根据最新协议,Rokit公司已承诺向20/20 Biolabs Inc报销经双方共同确认的销售与市场相关费用的三分之一。这一安排明确了双方在推广活动中的财务分担比例,为未来的合作奠定了基础。
根据最新协议,Rokit公司已承诺向20/20 Biolabs Inc报销经双方共同确认的销售与市场相关费用的三分之一。这一安排明确了双方在推广活动中的财务分担比例,为未来的合作奠定了基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.